1. Home
  2. CAPT vs QNRX Comparison

CAPT vs QNRX Comparison

Compare CAPT & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAPT

Captivision Inc.

N/A

Current Price

$0.42

Market Cap

13.2M

Sector

Finance

ML Signal

N/A

Logo Quoin Pharmaceuticals Ltd.

QNRX

Quoin Pharmaceuticals Ltd.

N/A

Current Price

$8.15

Market Cap

14.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPT
QNRX
Founded
2005
2018
Country
South Korea
United States
Employees
N/A
N/A
Industry
Blank Checks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
14.5M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
CAPT
QNRX
Price
$0.42
$8.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
152.1K
22.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.21
52 Week High
$1.93
$41.80

Technical Indicators

Market Signals
Indicator
CAPT
QNRX
Relative Strength Index (RSI) 43.83 38.37
Support Level $0.40 $6.85
Resistance Level $0.46 $9.93
Average True Range (ATR) 0.02 0.39
MACD 0.00 0.01
Stochastic Oscillator 43.40 0.00

Price Performance

Historical Comparison
CAPT
QNRX

About CAPT Captivision Inc.

Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Share on Social Networks: